Examining the effects of NOAC therapy on stroke severity and outcomes
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.
This study is testing how taking a specific type of blood thinner affects stroke severity and recovery in people with atrial fibrillation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT05283174 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between non-vitamin K antagonist oral anticoagulant (NOAC) therapy and the severity of acute strokes in patients with atrial fibrillation. It aims to analyze how adherence to NOAC treatment and drug levels at the time of stroke impact short-term and long-term outcomes. By measuring NOAC levels through blood sampling during acute stroke events, the study seeks to provide insights into optimal management strategies for stroke prevention in patients already on NOAC therapy.
Who should consider this trial
Good fit: Ideal candidates include patients with atrial fibrillation who are currently receiving NOAC therapy and have experienced an ischemic stroke, transient ischemic attack, or intracranial hemorrhage.
Not a fit: Patients who are not on NOAC therapy or those who refuse to provide blood samples for NOAC concentration measurement may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of stroke patients on NOAC therapy, leading to improved outcomes and tailored treatment strategies.
How similar studies have performed: While previous studies have explored the effects of NOAC therapy on stroke outcomes, this specific analysis of real-world data regarding NOAC adherence and drug levels in acute stroke is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Atrial fibrillation * Under dabigatran, rivaroxaban, apixaban or edoxaban therapy. * Developing ischemic stroke, transient ischemic attack or intracranial hemorrhage during NOAC therapy. Exclusion Criteria: * Refuse to provide blood sample for non-vitamin K antagonist oral anticoagulant (NOAC) concentration measurement. * Refuse to provide informed consent.
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Shin Yi Lin, MS
- Email: 102067@ntuh.gov.tw
- Phone: 0972651956
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.